Pembrolizumab in Early Triple-Negative Breast Cancer

被引：16

作者：

Ganguly, Shuvadeep ^{[1
]}

Gogia, Ajay ^{[1
]}

机构：

[1] All India Inst Med Sci, New Delhi, India

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 386卷 / 18期

关键词：

SURVIVAL; OUTCOMES;

D O I：

10.1056/NEJMc2203316

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: In the KEYNOTE-522 trial, Schmid et al.(1) reported that the addition of pembrolizumab to neoadjuvant chemotherapy for early triple-negative breast cancer resulted in an increased percentage of patients with a pathological complete response (no invasive cancer in the breast and negative nodes). In a recent analysis of this trial (Feb. 10 issue),(2) the authors found that the addition of pembrolizumab improved event-free survival among the patients. The improvement in this outcome was predominantly restricted to patients who had not had a pathological complete response; the 3-year event-free survival was 67.4% among such patients in the pembrolizumab group . . .

引用

页码：1771 / 1771

页数：1

共 9 条

[1] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[2]

Huang M, 2019, ANN ONCOL, V30, P34

[3] Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy [J].

Masuda, N. ;

Lee, S. -J. ;

Ohtani, S. ;

Im, Y. -H. ;

Lee, E. -S. ;

Yokota, I. ;

Kuroi, K. ;

Im, S. -A. ;

Park, B. -W. ;

Kim, S. -B. ;

Yanagita, Y. ;

Ohno, S. ;

Takao, S. ;

Aogi, K. ;

Iwata, H. ;

Jeong, J. ;

Kim, A. ;

Park, K. -H. ;

Sasano, H. ;

Ohashi, Y. ;

Toi, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2147-2159

[4] Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer [J].

Schmid, P. ;

Cortes, J. ;

Dent, R. ;

Pusztai, L. ;

McArthur, H. ;

Kummel, S. ;

Bergh, J. ;

Denkert, C. ;

Park, Y. H. ;

Hui, R. ;

Harbeck, N. ;

Takahashi, M. ;

Untch, M. ;

Fasching, P. A. ;

Cardoso, F. ;

Andersen, J. ;

Patt, D. ;

Danso, M. ;

Ferreira, M. ;

Mouret-Reynier, M-A ;

Im, S-A ;

Ahn, J-H ;

Gion, M. ;

Baron-Hay, S. ;

Boileau, J-F ;

Ding, Y. ;

Tryfonidis, K. ;

Aktan, G. ;

Karantza, V ;

O'Shaughnessy, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06) :556-567

[5]

Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI [10.1056/NEJMoa1910549, 10.1056/NEJMc2006684]

[6] CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). [J].

Sikov, William M. ;

Polley, Mei-Yin ;

Twohy, Erin ;

Perou, Charles M. ;

Singh, Baljit ;

Berry, Donald A. ;

Tolaney, Sara M. ;

Somlo, George ;

Port, Elisa R. ;

Ma, Cynthia X. ;

Kuzma, Charles S. ;

Mamounas, Eleftherios P. ;

Golshan, Mehra ;

Bellon, Jennifer Ruth ;

Collyar, Deborah E. ;

Hahn, Olwen Mary ;

Hudis, Clifford A. ;

Winer, Eric P. ;

Partridge, Ann H. ;

Carey, Lisa A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[7] Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients [J].

Spring, L. M. ;

Fell, G. ;

Arfe, A. ;

Trippa, L. ;

Greenup, R. ;

Reynolds, K. ;

Smith, B. L. ;

Moy, B. ;

Isakoff, S. J. ;

Parmigiani, G. ;

Bardia, A. .

CANCER RESEARCH, 2019, 79 (04)

[8] Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer [J].

Tutt, Andrew N. J. ;

Garber, Judy E. ;

Kaufman, Bella ;

Viale, Giuseppe ;

Fumagalli, Debora ;

Rastogi, Priya ;

Gelber, Richard D. ;

de Azambuja, Evandro ;

Fielding, Anitra ;

Balmana, Judith ;

Domchek, Susan M. ;

Gelmon, Karen A. ;

Hollingsworth, Simon J. ;

Korde, Larissa A. ;

Linderholm, Barbro ;

Bandos, Hanna ;

Senkus, E. ;

Suga, Jennifer M. ;

Shao, Z. ;

Pippas, Andrew W. ;

Nowecki, Zbigniew ;

Huzarski, Tomasz ;

Ganz, Patricia A. ;

Lucas, Peter C. ;

Baker, Nigel ;

Loibl, Sibylle ;

McConnell, Robin ;

Piccart, Martine ;

Schmutzler, Rita ;

Steger, Guenther G. ;

Costantino, Joseph P. ;

Arahmani, Amal ;

Wolmark, Norman ;

McFadden, Eleanor ;

Karantza, Vassiliki ;

Lakhani, Sunil R. ;

Yothers, Greg ;

Campbell, Christine ;

Geyer, Charles E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) :2394-2405

[9] Association of BRCA1-and BRCA2-deficiency with mutation burden, expression of PD-L1/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer [J].

Wen, Wei Xiong ;

Leong, Chee-Onn .

PLOS ONE, 2019, 14 (04)

← 1 →